NEW YORK, Dec. 29, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Outlook for Pharmaceutical Markets in Asia is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, plus comprehensive report sent annually. There are over 60 markets covered in the worldwide series.
These reports analyse the issues
The Outlook for Pharmaceutical Markets in Central Asia is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series.
Highlights from the region
India has a huge population in excess of one billion people and a growing middle class with access to high quality healthcare. Conversely, in this geographically vast country plagued by natural disasters, the majority of the population is both rural and poor and western style pharmaceuticals are not even an issue for millions of people. India has an established domestic industry, responsible for around 8% of world pharmaceutical production. The larger domestic companies are striving to compete in the global market for both generics and original products. The market is dominated by low priced, domestically-produced generics and relatively low per capita expenditure on pharmaceuticals.
China's pharmaceutical market looks set to grow even further in the short-term, with the establishment of an Essential Medicines System during the 2009-2011 period. The plan calls for an estimated 300-400 essential medicines to be made available at all public facilities, starting at the grassroots level. In October 2009, the NDRC reduced the prices of 2,349 drugs by an average 12%. These drugs represent around 45% of drugs on the Essential Medicines System. The prices of 49% of drugs on the list will not be reduced while the remaining 6% that are in short supply will see their prices increased moderately in order to encourage their manufacture.
The Pakistani pharmaceutical market has slowly evolved over the years, from one that was largely dominated by multinationals around 20 years ago, to one that is now almost evenly split between local and multinational companies. Increased competition, low drug prices, rising raw material costs, poor intellectual property rights and generally weak market conditions brought on by economic and political instability has made the country somewhat less attractive to some multinational companies. The domestic pharmaceutical industry serves an estimated 80% of the market. Ferozsons Laboratories has formed a joint-venture with the Argentine Bago group to build the first biotech manufacturing plant in Pakistan.
The country is the eighth most populous on earth but it is very poor. There is a marked disparity in the standard of healthcare between rural and urban areas. The capital city Dhaka enjoys a higher standard of primary care, and is home to a modest but growing private sector while healthcare coverage in remote regions remains insufficient. There is potential for joint ventures and business partnerships in the pharmaceutical sector between Bangladesh and India which would enable Bangladesh to tap into superior Indian resources and expertise. Beximco, the first Bangladeshi company to be floated on the London Stock Exchange, has an 8% share of the local finished formulations market, as well as 40% of the infusions sector.
To order this report:
US: (805) 652-2626
Intl: +1 805-652-2626